Ana SayuriYamagata1, Elisa Brietzke2, Joshua D Rosenblat3, Ron Kakar3, Roger S McIntyre4. 1. University of São Paulo (USP), São Paulo, Brazil; Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Federal University of São Paulo (Unifesp), São Paulo, Brazil. 2. Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Federal University of São Paulo (Unifesp), São Paulo, Brazil. 3. Mood Disorders Psychopharmacology Unit (MDPU), University Health Network (UHN), University of Toronto, Toronto, Canada. 4. Mood Disorders Psychopharmacology Unit (MDPU), University Health Network (UHN), University of Toronto, Toronto, Canada. Electronic address: roger.mcintyre@uhn.ca.
Abstract
BACKGROUND: Bipolar disorder (BD) is associated with chronic low-grade inflammation, several medical comorbidities and a decreased life expectancy. Metabolic-inflammatory changes have been postulated as one of the main links between BD and medical comorbidity, although there are few studies exploring possible mechanisms underlying this relationship. Therefore, the aims of the current narrative review were 1) synthesize the evidence for metabolic-inflammatory changes that may facilitate the link between medical comorbidity and BD and 2) discuss therapeutic and preventive implications of these pathways. METHODS: The PubMed and Google Scholar databases were searched for relevant studies. RESULTS: Identified studies suggested that there is an increased risk of medical comorbidities, such as autoimmune disorders, obesity, diabetes and cardiovascular disease in patients with BD. The association between BD and general medical comorbidities seems to be bidirectional and potentially mediated by immune dysfunction. Targeting the metabolic-inflammatory-mood pathway may potential yield improved outcomes in BD; however, further study is needed to determine which specific interventions may be beneficial. LIMITATIONS: The majority of identified studies had cross-sectional designs, small sample sizes and limited measurements of inflammation. CONCLUSIONS: Treatment and prevention of general medical comorbidities in mood disorders should include preferential prescribing of metabolically neutral agents and adjunctive lifestyle modifications including increased physical activity, improved diet and decreased substance abuse. In addition, the use of anti-inflammatory agents could be a relevant therapeutic target in future research.
BACKGROUND:Bipolar disorder (BD) is associated with chronic low-grade inflammation, several medical comorbidities and a decreased life expectancy. Metabolic-inflammatory changes have been postulated as one of the main links between BD and medical comorbidity, although there are few studies exploring possible mechanisms underlying this relationship. Therefore, the aims of the current narrative review were 1) synthesize the evidence for metabolic-inflammatory changes that may facilitate the link between medical comorbidity and BD and 2) discuss therapeutic and preventive implications of these pathways. METHODS: The PubMed and Google Scholar databases were searched for relevant studies. RESULTS: Identified studies suggested that there is an increased risk of medical comorbidities, such as autoimmune disorders, obesity, diabetes and cardiovascular disease in patients with BD. The association between BD and general medical comorbidities seems to be bidirectional and potentially mediated by immune dysfunction. Targeting the metabolic-inflammatory-mood pathway may potential yield improved outcomes in BD; however, further study is needed to determine which specific interventions may be beneficial. LIMITATIONS: The majority of identified studies had cross-sectional designs, small sample sizes and limited measurements of inflammation. CONCLUSIONS: Treatment and prevention of general medical comorbidities in mood disorders should include preferential prescribing of metabolically neutral agents and adjunctive lifestyle modifications including increased physical activity, improved diet and decreased substance abuse. In addition, the use of anti-inflammatory agents could be a relevant therapeutic target in future research.
Authors: Gabriela D Colpo; Marion Leboyer; Robert Dantzer; Mahdukar H Trivedi; Antonio L Teixeira Journal: Expert Rev Neurother Date: 2017-11-27 Impact factor: 4.618
Authors: Ana Catarina Pereira; Jessica De Pascale; Rosa Resende; Susana Cardoso; Isabel Ferreira; Bruno Miguel Neves; Mylène A Carrascal; Mónica Zuzarte; Nuno Madeira; Sofia Morais; António Macedo; Anália do Carmo; Paula I Moreira; Maria Teresa Cruz; Cláudia F Pereira Journal: Cell Mol Life Sci Date: 2022-03-28 Impact factor: 9.261
Authors: Roger S McIntyre; Martin Alda; Ross J Baldessarini; Michael Bauer; Michael Berk; Christoph U Correll; Andrea Fagiolini; Kostas Fountoulakis; Mark A Frye; Heinz Grunze; Lars V Kessing; David J Miklowitz; Gordon Parker; Robert M Post; Alan C Swann; Trisha Suppes; Eduard Vieta; Allan Young; Mario Maj Journal: World Psychiatry Date: 2022-10 Impact factor: 79.683
Authors: Lucas B Rizzo; Walter Swardfager; Pawan Kumar Maurya; Maiara Zeni Graiff; Mariana Pedrini; Elson Asevedo; Ana Cláudia Cassinelli; Moisés E Bauer; Quirino Cordeiro; Jan Scott; Elisa Brietzke; Hugo Cogo-Moreira Journal: Int J Methods Psychiatr Res Date: 2018-04-25 Impact factor: 4.035
Authors: Fernanda Barbisan; Verônica Farina Azzolin; Cibele Ferreira Teixeira; Moisés Henrique Mastella; Euler Esteves Ribeiro; Pedro Antonio Schmidt do Prado-Lima; Raquel de Souza Praia; Marta Maria Medeiros Frescura Duarte; Ivana Beatrice Mânica da Cruz Journal: Biomed Res Int Date: 2017-11-08 Impact factor: 3.411